My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 11 777 /


Proton radiobiology and its clinical implications

Denser ionisation clustering and complex DNA damage in proton Bragg peaks far exceeds that seen with conventional X-rays. This results in more efficient cell sterilisation, quantified by the relative biological effectiveness (RBE). Currently, a 1.1 RBE is used to determine the clinical proton doses by dividing the usual X-rays dose by this amount. This number, derived from short-term experiments, has been criticised as being irrelevant to late normal tissue (NT) effects following radiotherapy and included many control irradiations using lower voltage X-rays (with elevated RBE values) than those used in the clinic. In principle, an increased RBE could be used for each organ at risk, by using extensions of the clinically successful linear quadratic model.

Protons undoubtedly reduce or eliminate NT radiation dose in tissues distantly located from a tumour, but the necessity to include NT margins around a tumour can result in a higher volume of NT than tumour being irradiated. Deleterious side-effects can follow if the NT RBE exceeds 1.1, including in tissue very close to these margins and which are only partially spared.

Use of a constant 1.1 RBE can ‘overdose’ NT, which may require a greater dose reduction such as 1.2 in the brain; some tumours may be ‘under-dosed’ (since they might require a lesser or no reduction in dose). More sophisticated proton experiments show that RBE values of 1.1–1.5 and higher occur in some situations. There are now mathematical models of varying degrees of complexity that can estimate the RBE from the dose, LET and the low-LET radiosensitivities. True multidisciplinary cooperation is required to implement such new ideas in proton therapy in order to improve safety and effectiveness.

Keywords: proton therapy, radiobiology, RBE, linear energy transfer, cancer, ICRU



Loading Article Metrics ... Please wait

Related articles

Review: Cystic brain metastases in ALK-rearranged non-small cell lung cancer

Abstract | Full Article | PDF Published: 14 Mar 2018 /

Case Report: Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma

Abstract | Full Article | PDF | Spanish Published: 05 Mar 2018 /

Special Issue: Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome

Abstract | Full Article | PDF Published: 30 Nov 2017 /

Special Issue: Recent advances in radiation oncology

Abstract | Full Article | PDF Published: 30 Nov 2017 /

Special Issue: History of the development of radiotherapy in Latin America

Abstract | Full Article | PDF Published: 30 Nov 2017 /

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence